Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVG-101
- Development stage
- Preclinical
- Lead developer
- AaviGen
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
AVG-101 is a preclinical-stage gene therapy candidate developed by AaviGen for the treatment of heart failure. It utilizes a heart-specific adeno-associated viral (AAV) vector technology to deliver therapeutic genes directly to cardiac tissue. The therapy is designed to improve cardiac function by promoting cardioprotection, enhancing cardiac contractility, and supporting energy metabolism within the heart. AaviGen has partnered with SK pharmteco for the strategic manufacturing of AVG-101 to support its clinical development. The proprietary AAV vector platform used for AVG-101 is engineered for high cardiac tropism and reduced liver uptake, aiming to improve the safety and efficacy profile of the gene therapy.
Beyond the preview
Go deeper on AVG-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVG-101.